10-K: Denali Capital Acquisition Corp. Faces Going Concern Uncertainty Amidst Semnur Merger

Denali Capital Acquisition Corp.'s annual report reveals substantial doubt about its ability to continue as a going concern, despite efforts to merge with Semnur Pharmaceuticals.

Summary

• Denali Capital Acquisition Corp., a blank check company, filed its annual report for the year ended December 31, 2024.
• The company's primary focus has been identifying a target for a business combination, with a proposed merger with Semnur Pharmaceuticals, Inc.
• The report highlights substantial doubt about Denali's ability to continue as a going concern due to its upcoming deadline to complete a business combination by April 11, 2025, and its limited capital resources.
• Denali consummated its IPO in April 2022, raising gross proceeds of $82.5 million, and simultaneously sold Private Placement Units to its sponsor for $5.1 million.
• The company has faced challenges in completing a business combination, including the termination of a previous merger agreement with Longevity Biomedical, Inc.
• To extend the period for completing a business combination, Denali has secured convertible promissory notes from its sponsor and Scilex Holding Company, totaling up to $180,000 each.
• Shareholders holding 3,785,992 public shares redeemed their shares in July 2024, removing approximately $43.4 million from the Trust Account.
• As of December 31, 2024, Denali held $9,021,005 in its Trust Account and $16,868 outside the Trust Account.
• The company reported a net loss of $167,306 for the year ended December 31, 2024, primarily due to formation and operating expenses.
• Denali is subject to Nasdaq listing rules and has received notices regarding non-compliance with minimum value of listed securities and total assets requirements.
• The company's ability to continue as a going concern is dependent on its ability to complete a business combination by April 11, 2025.
• The report includes forward-looking statements and outlines various risks and uncertainties associated with Denali's operations and the proposed business combination with Semnur.

Sentiment

Score: 3

Explanation: The document presents a concerning outlook due to the going concern warning, Nasdaq non-compliance, and net losses, offset slightly by ongoing merger efforts and financing secured.

Positives

• Denali has secured agreements for convertible promissory notes to extend the period for completing a business combination.
• The company is actively pursuing a business combination with Semnur Pharmaceuticals, Inc.
• Management is taking steps to address Nasdaq listing deficiencies.

Negatives

• The company faces 'substantial doubt' about its ability to continue as a going concern.
• Denali is not in compliance with Nasdaq listing rules regarding minimum value of listed securities and total assets.
• The company incurred a net loss of $167,306 for the year ended December 31, 2024.
• Significant shareholder redemptions have reduced the funds available in the Trust Account.

Risks

• The company may not be able to complete its initial business combination within the prescribed time frame.
• The net proceeds of the IPO and the sale of the Private Placement Units not being held in the Trust Account may be insufficient to allow the company to operate until the Extended Date.
• Attractive targets may become scarcer and there may be more competition for attractive targets.
• The company's shareholders will not be entitled to protections normally afforded to investors of many other blank check companies.
• The company may not have sufficient funds to satisfy indemnification claims of its directors and executive officers.
• The company may be a passive foreign investment company, or PFIC, which could result in adverse U.S. federal income tax consequences to U.S. investors.
• Potential economic downturns may lead to increased difficulty in completing the business combination.
• Recent volatility in capital markets may affect the company's ability to obtain financing for the business combination through sales of its ordinary shares or issuance of indebtedness.
• Military conflict in Ukraine, the Middle East, or elsewhere may lead to increased price volatility for public traded securities, which could make it difficult for the company to consummate its business combination.
• Nasdaq will suspend trading of the company's securities and commence delisting proceedings on or about April 7, 2025 due to the company's failure satisfy listing rule IM-5101-2 to consummate a business combination within 36 months of effectiveness of its initial public offering registration statement, which will adversely affect the trading market for the company's securities and may impair the company's ability to complete a business combination.

Future Outlook

The company's future is contingent on completing a business combination with Semnur Pharmaceuticals by April 11, 2025, or a potential extended deadline, and obtaining necessary approvals and financing.

Industry Context

The announcement reflects the challenges faced by SPACs in the current market environment, including difficulties in identifying suitable targets and securing shareholder support for business combinations.

Comparison to Industry Standards

• Given the current market conditions, many SPACs are facing challenges in completing mergers within their initial timeframes, leading to liquidations or extensions.
• The high redemption rates experienced by Denali are consistent with trends observed in other SPAC transactions, reflecting investor uncertainty and the availability of alternative investment opportunities.
• The reliance on convertible notes from sponsors and related parties for operational funding is a common practice among SPACs seeking to extend their operational runway.

Related Party Transactions

• Issuance of founder shares to the sponsor.
• Purchase of Private Placement Units by the sponsor.
• Convertible promissory notes issued to the sponsor.
• Sponsor Interest Purchase Agreement between the sponsor and Scilex.

Stakeholder Impact

• Shareholders face uncertainty regarding the completion of a business combination and the potential for liquidation.
• Employees may be affected by the company's financial instability and potential liquidation.
• The target business, Semnur Pharmaceuticals, faces uncertainty regarding the completion of the merger.

Next Steps

• The company must obtain shareholder approval for the proposed business combination with Semnur Pharmaceuticals.
• The company must complete the business combination by April 11, 2025, or a potential extended deadline.
• The company must regain compliance with Nasdaq listing rules.

Key Dates

Keywords

business combination, SPAC, merger, Denali Capital Acquisition Corp, Semnur Pharmaceuticals, going concern, Trust Account, redemption, Nasdaq, IPO, convertible notes, liquidation